Silvant Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Silvant Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.49M	Buy	20,706 +100	+0.5%	+$14.8K	0.1%	124
2026 Q1	$2.71M	Buy	20,606 +333	+2%	+$44.2K	0.09%	120
2025 Q4	$2.88M	Buy	20,273 +326	+2%	+$47.2K	0.1%	114
2025 Q3	$2.8M	Sell	19,947 -1,886	-9%	-$256K	0.1%	113
2025 Q2	$2.74M	Hold	21,833	–	–	0.1%	113
2025 Q1	$2.41M	Hold	21,833	–	–	0.11%	112
2024 Q4	$2.98M	Hold	21,833	–	–	0.12%	103
2024 Q3	$2.52M	Hold	21,833	–	–	0.11%	112
2024 Q2	$3.01M	Buy	21,833 +3,539	+19%	+$485K	0.13%	100
2024 Q1	$2.52M	Hold	18,294	–	–	0.12%	105
2023 Q4	$2.41M	Hold	18,294	–	–	0.13%	103
2023 Q3	$2.06M	Hold	18,294	–	–	0.12%	105
2023 Q2	$1.73M	Hold	18,294	–	–	0.1%	119
2023 Q1	$1.85M	Hold	18,294	–	–	0.12%	109
2022 Q4	$2.19M	Buy	+18,294	New	+$2.14M	0.15%	106
2019 Q2	–	Sell	-3,038	Closed	-$268K	–	340
2019 Q1	$268K	Hold	3,038	–	–	0.05%	164
2018 Q4	$217K	Sell	3,038 -995	-25%	-$95.3K	0.04%	169
2018 Q3	$496K	Hold	4,033	–	–	0.06%	126
2018 Q2	$396K	Hold	4,033	–	–	0.05%	136
2018 Q1	$334K	Buy	+4,033	New	+$341K	0.04%	156

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Silvant Capital Management's NBIX Position: Q2 2026 in Review

Silvant Capital Management increased its Neurocrine Biosciences (NBIX) stake by 0.49% in Q2 2026, buying an estimated $14.8K and bringing the position to 20,706 shares worth $3.49M. The position accounts for 0.1% of the portfolio, ranked #124.

Silvant Capital Management first reported a position in NBIX in Q1 2018 and has held it in 20 quarters since. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Silvant Capital Management held 20,706 shares of Neurocrine Biosciences worth $3.49M as of Q2 2026.
Silvant Capital Management bought 100 Neurocrine Biosciences shares in Q2 2026, an estimated $14.8K.
Neurocrine Biosciences made up 0.1% of Silvant Capital Management's portfolio in Q2 2026, its #124 holding.
Silvant Capital Management first reported a position in Neurocrine Biosciences in Q1 2018 and has held it in 20 quarters since.
781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Silvant Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.